Methods and compositions for diagnosing Alzheimer’s disease and age-related macular degeneration

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The The Board Of Regents Of The University Of Oklahoma patent solves the following problem:

The presently disclosed inventive concept (s) related to, but not limited to, anti-CAP37 antibody, isoforms of CAP37, methods to identify chronic and acute inflammatory-associated disease, and methods of treatment using anti-CAP37 antibody.

Our analysis of this patent is as follows:

The Board Of Regents Of The University Of Oklahoma’s patent US 9399675 B2 deals with Methods and compositions for diagnosing Alzheimer’s disease and age-related macular degeneration.
Composition comprising monoclonal antibody against CAP37 (Cationic antimicrobial protein of Mr 37 kDa) and its isoforms, with the antigen binding fragments thereof, disclosed. The antibody used in the diagnosis and early detection of Alzheimer's Disease and Age-Related macular degeneration.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Human antibodies to Clostridium difficile toxins

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Regeneron Pharmaceuticals, Inc. patent solves the following problem:

Our analysis of this patent is as follows:

Regeneron Pharmaceuticals, Inc.’s patent US 9399674 B2 deals with Human antibodies to Clostridium difficile toxins.
The present invention provides fully human antibodies that bind to either toxin A or toxin B of Clostridium difficile toxin A and toxin B, compositions comprising the antibodies and methods of use. The antibody of the invention is useful for neutralizing toxins from C. difficile, thus providing a way to treat the pain and symptoms associated with a C. difficile infection, including treatment diarrhea, pseudomembranous colitis due to C. difficile. The antibody may also hinder the severity and / or duration of the disease, or to control the number, duration, and / or severity of recurrences, or of illness attributed to the presence of C. difficile. The antibody of the invention may also be useful for the diagnosis of an infection with C. difficile.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

VHNAR anti-cytokine domains

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Laboratories Silanes S.A. De C.V. patent solves the following problem:

Our analysis of this patent is as follows:

Laboratories Silanes S.A. De C.V.’s patent US 9399677 B2 deals with VHNAR anti-cytokine domains.
The present invention concerns therapeutic compositions of proteins that are the variable region of the immunoglobulin IGNAR, called vNAR, which specifically binds and neutralizes cytokines involved in a diversity of processes such as inflammation and neovascularization, its ability to reach, here, and neutralize the activity of an antigenic molecules localized in a immunoprivileged organs, are also described.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Compositions and methods for growth factor modulation

Be the First-to-File and Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Scholar Rock, Inc. patent solves the following problem:

Cell signaling molecules that stimulate a variety of cellular activities. The signal is usually tightly controlled, often through partnerships with other biomolecules, the extracellular and / or cellular matrix or within a particular cell environment or niche. The association may directly or indirectly.

Our analysis of this patent is as follows:

Scholar Rock, Inc.’s patent US 9399676 B2 deals with Compositions and methods for growth factor modulation.
If there are proteins, antibodies, assays and methods useful for modulating the levels of growth factors and / or activities. In some embodiments, the growth factors are members of the TGF- type of protein.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for producing proteins

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Ucb Pharma S.A. patent solves the following problem:

Our analysis of this patent is as follows:

Ucb Pharma S.A.’s patent US 9399671 B2 deals with Method for producing proteins.
The invention relates to a transcriptionally active artificial linear polynucleotide encoding a multimeric protein comprising the following order, a first promoter sequences, a first polynucleotide encoding a bidirectional regulatory, a second polynucleotide encoding and a second promoter, wherein the first and second sequences encoding polynucleotide is convergent transcriptional orientation, each encoding polynucleotide sequences encoding a portion multimeric protein and the bidirectional regulatory sequence is operably linked to the first and second polynucleotide encoding sequences and the multimeric protein is an antibody or fragment thereof, and each polynucleotide sequence encoding are- encoding one or more antibody domains, or fragments thereof.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Method for obtaining immunoglobulin encoding nucleic acid

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Hoffmann-La Roche Inc. patent solves the following problem:

Since the establishment of the hybridoma technology (Cole, SPC, et al, Monoclonal antibody and Cancer Therapy, Alan R. Liss, p 77 (1985); …. and Boerner, P., et al, J. Immunol 147 (1991 ) 86-95), monoclonal immunoglobulin appeared to play an important role in scientific research, human healthcare and diagnostics. Therefore, the generation of monoclonal, especially therapeutic, immunoglobulin a field undergoing intensive research. In its honor, the hybridoma technology and phage display technology (Hoogenboom, HR, and Winter, G., J. mol Biol 227 (1992) 381-388; Marks, JD, et al, J. mol Biol … 222 (1991) 581-597) was, among others, two commonly used technology for the generation of monoclonal immunoglobulin. Hybridoma technology have the strong clones is a hurdle, thus, diminishing differences in antibody, as only a limited number of B-cells successfully fused, propagated and afterward described. Similarly, one drawback of phage or yeast display-based combinatorial library methods are randomly paired immunoglobulin heavy and light chains. The dissociation of the original heavy and light chain pairing, and non-cognate pairing, requires the screening of a large number of immunoglobulin cells to recognize the heavy and light chains paris high aunt. Moreover, the non-cognate pairs may show no cross-reactivity to human antigens. In the end, the genetic diversity of target-specific immunoglobulin identified in the selection and screening of combinatorial libraries are often limited because of inherent selection bias.

Our analysis of this patent is as follows:

Hoffmann-La Roche Inc.’s patent US 9399670 B2 deals with Method for obtaining immunoglobulin encoding nucleic acid.
The present invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a cell comprising the following steps: performing a first polymerase reaction in three to six 5-primer and a 3-primer, performing products in the polymerase chain reaction with a second polymerase reaction thirteen to sixteen 5-primer a 3-primer, where the distance from the binding sites in primer used in the second polymerase chain reaction is reduced compared to the first chain reaction polymerase.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Gram-positive bacteria specific binding compounds

Protect your idea by filing a Provisional or Utility Patent Application with the PowerPatent Patent Service. It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.

The Genentech, Inc., , Aimm Therapeutics B.V. patent solves the following problem:

Program-positive microorganisms cause many systemic infections. An important member of the gram-positive pathogens are Staphylococcus aureus (S. aureus). 20% of the population is a long-term carrier of S. aureus. S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses , life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia. S. aureus is capable of infecting all kinds of organs and tissues. S. aureus infection occur in immunocompetent as well as in immune compromised people. 50% of infections in US intensive unit care causing pathogen. Three hundred thousand S. aureus infections every year, resulting in 12,000 deaths, reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).

Our analysis of this patent is as follows:

Genentech, Inc., , Aimm Therapeutics B.V.’s patent US 9399673 B2 deals with Gram-positive bacteria specific binding compounds.
The present invention provides improved value compounds can specifically bind gram-positive bacteria. Binding compounds which are fully human, so that therapeutic applications of human individuals.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Hepatitis C virus neutralizing antibody

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time for Utility, Provisional or Design Patent Creation with PowerPatent software and services.

The The United States Of America, As Represented By The Secretary Department Of Health And Human Services patent solves the following problem:

Hepatitis C is an infectious disease affecting primarily the liver because of hepatitis C virus (HCV). HCV is a major pathogen transmitted through infected blood that infects 170 million people worldwide. Infection may remain hidden without showing symptoms of the year, and many people do not know they are infected.

Our analysis of this patent is as follows:

The United States Of America, As Represented By The Secretary Department Of Health And Human Services’s patent US 9399672 B2 deals with Hepatitis C virus neutralizing antibody.
A specific epitope on the surface of the hepatitis C virus to accelerate the formulation of a neutralizing antibody response in vivo and neutralizing monoclonal antibody that binds specifically to the epitope expressed. The antibody block hepatitis C virus from infecting cells.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Therapeutic anti-TIRC7 antibodies for use in immune related and other diseases

You’ve invested time, talent, and energy into making a dent in the universe with your invention and ideas. Now it’s time to make sure it’s protected with a PowerPatent Utility, Provisional or Design Patent Application

The Nalan Utku patent solves the following problem:

The present invention relates to anti-T-cell immune response cDNA 7 (TIRC7) antibody and uses thereof. In particular, the anti-TIRC7 antibody of the invention is able to prevent the proliferation of activated cells in the immune system. Furthermore, the present invention relates to compositions comprising said antibody, and methods of modulating immune cell proliferation, and treating immune response related diseases.

Our analysis of this patent is as follows:

Nalan Utku’s patent US 9399679 B2 deals with Therapeutic anti-TIRC7 antibodies for use in immune related and other diseases.
If the specific antibody against the T-cell immune response cDNA7 (TIRC7) costimulatory molecules, capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibody described. Compositions comprising these antibodies and their use for the treatment of immune diseases given.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.

Anti-tumor necrosis factor-alpha agents and uses thereof

Patent Registration – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application

The Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa patent solves the following problem:

Tumor necrosis factors alpha (TNF-alpha) is a cytokine that is as a trimeric molecule and has two bioactive formsmembrane-bound TNF-alpha and soluble TNF-alpha. The membrane bound form of TNF-alpha comprising the extracellular, transmembrane and cytoplasmic domains. Cleavage of membrane bound form (26 kDa), resulting in soluble form (17 kDa), which is as a homodimer. While two types of biologically active, soluble forms of TNF-alpha stronger.

Our analysis of this patent is as follows:

Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa’s patent US 9399678 B2 deals with Anti-tumor necrosis factor-alpha agents and uses thereof.
The present invention relates to polypeptides comprising one or more antibody domains, or antigen-binding fragment thereof, directed against tumor necrosis factor-alpha, in particular, two light chain variable domain of the dimeric form, wherein the dimer has high solubility. It also relates to methods of using the anti-tumor necrosis factor-alpha polypeptides for the treatment of inflammatory diseases, including rheumatoid arthritis. Compositions and methods for improving the therapeutic potential of anti-tumor necrosis factor-alpha polypeptides given, including linking the polypeptide to an albumin-binding domain and / or de-polypeptide vaccine, providing therapeutic agents with good solubility, increased serum half-life and / or reduced immunogenicity, while substantially maintaining the specific value of property in anti-tumor necrosis factor-alpha polypeptides.

The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.